Articles tagged with Lung Cancer
A study found that older age, lower education levels and longer smoking history are associated with a positive lung cancer diagnosis after an abnormal screening chest radiograph. A family history of lung cancer and suspicious masses also contribute to a true positive diagnosis.
A Phase III trial found that vandetanib significantly improved progression-free survival compared to chemotherapy alone. The therapy, which targets both EGFR and VEGFR, also showed reduced side effects, particularly nausea and vomiting.
A new study finds that exposure to particulate matter can reprogram genes associated with tumor suppression, affecting cancer development and outcomes. The changes are detectable after just three days of exposure, raising hopes for early interventions to prevent or reverse gene programming.
A Canadian Cancer Society-funded study will investigate the risk of bladder and kidney cancer associated with environmental exposure to arsenic in drinking water. Dr Louise Parker's three-year research project aims to help policy-makers decide whether new approaches to water testing and treatment are needed.
Researchers found that exercise programs significantly reduced lung cancer symptoms in patients who completed the study, with no deterioration in functional capacity or muscle strength. The study suggests that community-based or shorter exercise programs may be more feasible for lung cancer patients to complete.
A study found that patients diagnosed with lung cancer through CT scans had a significantly higher 5-year survival rate (91.2%) compared to those diagnosed with x-rays (77.8%). The study suggests that early detection of the disease using CT scans improves patient prognosis.
Researchers are launching a multi-institutional effort to develop a test to detect early-stage lung cancer in lifetime nonsmokers. The project aims to create a better understanding of the biology of lung cancer and identify potential biomarkers.
Researchers discuss personalized treatment options for early-stage lung cancer, using targeted therapies and cancer vaccines. A gene signature is being used to predict which patients will benefit from an immune-boosting vaccine designed to target MAGE-A3 protein.
Researchers found women tend to be younger when developing lung cancer, despite smoking less than men, increasing the risk of tobacco carcinogens. Women's awareness of other cancers like breast cancer may also contribute to their vulnerability, with median survival after surgery being longer for women.
Researchers present new techniques for early diagnosis and treatment of lung cancer, improving 5-year survival rates from 10% to 70%. A new factor that correlates with clinical parameters may also help indicate patient prognosis.
A phase III study found that adding cetuximab to standard chemotherapy for non-small-cell lung cancer (NSCLC) extends survival by almost one month compared to chemotherapy alone. The treatment has been shown to target epidermal growth factor receptor, which plays a key role in tumour growth.
A large prospective case-cohort study found no association between dietary acrylamide intake and lung cancer risk in men, but suggested an inverse association in women. The researchers hypothesize that acrylamide may affect hormonal balances to explain the findings.
Researchers are exploring new treatments for lung cancer using targeted therapies and personalized care. Studies have shown promising results in improving patient outcomes, including the use of molecular targeted therapies and chemotherapy combinations.
A new report reveals a significant increase in the number of people diagnosed with cancer in Ireland, but also shows that survival rates are rising for certain types of cancer. The report highlights the importance of prevention and early detection in reducing the burden of cancer.
Notch1 contributes to lung fibrosis by increasing myofibroblasts, while SOCS-1 inhibits prostate cancer growth. TIP30 prevents lung cancer metastasis, and SPARC accelerates kidney disease progression. These findings highlight potential new therapeutic targets.
A computer-aided detection system has been shown to detect 45-55% of overlooked lung cancer nodules, potentially leading to earlier diagnosis and improved survival rates. The study suggests that CAD software can assist radiologists in identifying subtle signs of early lung cancer.
Researchers at Washington University School of Medicine have uncovered the genetic source of pleuropulmonary blastoma (PPB), a rare and aggressive childhood lung cancer. The study found that some children with PPB are born with deleterious mutations in the DICER1 gene, which is involved in regulating gene expression.
Human lung tumors can destroy Vitamin D, a hormone with anti-cancer properties, according to a new study. The researchers developed a test to measure Vitamin D levels in tissues and blood, which could help identify the best approaches to maintain therapeutic levels of Vitamin D.
Researchers found that a urine metabolite called NNAL predicts risk of lung cancer in smokers, with higher levels associated with increased risk. The study, published by the American Association for Cancer Research, analyzed data from over 50,000 patients.
Scientists at the University of Cincinnati have identified the RGS17 gene as a major suspect in familial lung cancers. Further investigation may lead to genetic testing for high-risk patients, enabling early detection and treatment.
A study found that black patients with non-small cell lung cancer are 37% less likely to receive recommended surgery and 42% less likely to receive recommended chemotherapy than white patients. The disparity remains despite efforts to address inequalities in medical treatment.
A new study by researchers at the University of Michigan Comprehensive Cancer Center found that higher doses of radiation combined with chemotherapy improve survival in patients with stage III lung cancer. Concurrent chemotherapy increases treatment effectiveness and overall survival rates.
A large cohort study found that long-term survivors of hereditary retinoblastoma are at a significantly increased risk of death due to subsequent cancers. Hereditary retinoblastoma survivors had a 35-fold higher mortality rate compared to the general population.
A retrospective analysis found that multiple lung tumors in patients often arise from a single cancer cell, suggesting multifocal lung cancers should be classified as advanced-stage cancers. The study analyzed 70 tumor samples and concluded that 77% of patients had multiple tumors originating from a single clone.
Researchers at UVA Health System found that SRC gene promotes growth suppression in bladder cancer, contradicting its role in most cancers. The study suggests caution when using targeted therapeutic agents that inhibit SRC in bladder cancer treatment.
Researchers found that cetuximab's success in treating non-small cell lung cancer depends on the production of a specific protein called u-PAR. Higher levels of u-PAR indicate reduced responsiveness to the treatment, suggesting it could be used as a biomarker.
A new technique called stereotactic body radiotherapy (SBRT) has been shown to significantly improve survival rates for early-stage lung cancer patients, with a median survival range of over 32 months. The treatment doubles the odds of surviving and can even cure at least half of the patients, offering hope without the need for surgery.
A recent study found that socioeconomic status is linked to an increased risk of developing lung cancer, with Europeans having lower education levels experiencing a higher incidence. The research suggests that while smoking accounts for approximately half of this risk, diet and other factors also play a role in the disparity.
Researchers at Wake Forest University have developed a new class of platinum-based anti-tumor drugs that demonstrate 10 times greater efficacy than current treatments against certain lung cancer types. The compounds work by rapidly binding with and disabling tumor cell DNA, potentially overcoming drug resistance issues.
Survivors of early-stage lung cancer who engage in regular physical activity experience improved mood, vigor, and physical functioning. Moderate exercise, such as brisk walking a few times a week, may promote better quality of life and reduce depressive symptoms.
The 2009 awards recognize groundbreaking work in early detection of ovarian and lung cancers, improvements to bone marrow transplant safety, and discovery of new genetic markers for cancer. The $450,000 prize will support the projects over three years.
A recent UC Davis study found that smoking is linked to over 70% of cancer death burden among Massachusetts men in 2003, surpassing previous estimates. The study suggests that increased tobacco control efforts could save more lives and improve health outcomes.
A study examines racial disparities in survival among black patients diagnosed with early-stage lung cancer. Despite recommended treatment, black patients have lower five-year survival rates compared to white patients.
National Lung Cancer Partnership awards I-Ching Wang a Career Development Award to study FoxM1, a protein linked to aggressive lung cancer growth. The grant aims to support protein-directed therapies and control the leading US cancer killer. Dr. Wang's research will help combat underfunding in federal lung cancer research.
The National Lung Cancer Partnership and LUNGevity Foundation have awarded $100,000 research grants to Prasad Adusumilli and Lee Goodglick. Dr. Adusumilli's study will investigate visceral pleural invasion, while Dr. Goodglick's research focuses on estrogen's role in lung cancer.
A recent study by Boston University researchers has identified a class of microRNAs that regulate gene expression changes in airway cells caused by smoking and lung cancer. These findings may lead to a non-invasive biomarker for smoking-related lung diseases, improving early diagnosis and treatment options.
Researchers at the University of Cincinnati have identified a new tumor suppressor, protein kinase C-zeta, that may help develop targeted drug therapies to combat lung cancer. The study found that PKC-zeta normally slows down Ras transformation and prevents tumor development, but its absence or inactivity accelerates cancer growth.
A research team at UC San Diego has identified a protein called versican that enhances metastasis by stimulating inflammatory cells. Versican is found in low amounts in normal lung epithelial cells but is upregulated in aggressive lung tumors, supporting the growth and spread of cancer.
Researchers found that silencing of a crucial gene in lung cancer leads to impairment in genome-wide changes, contributing to cancer development and progression. Tobacco use is strongly linked to modification of the MTHFR gene, which triggers global hypomethylation and deregulation of DNA synthesis.
Research suggests that high intake of inorganic phosphates, found in processed foods, can stimulate lung cancer development and growth. Dietary regulation of phosphates may play a critical role in treatment and prevention of the disease.
Research identified common variants in ABCB1 and ABCC1 genes that increase lung cancer risk. Variants were found more often in patients than controls, particularly in women and younger individuals. These findings may help prevent tobacco-related cancers.
Researchers have identified a gene mutation in SFTPA2 that is linked to an inherited form of idiopathic pulmonary fibrosis, a lethal lung disease affecting older adults. The same mutation is also associated with lung cancer.
Researchers at University of Nottingham identified the tumour suppressor gene LIMD1 as a protector against lung cancer. The study found that LIMD1 was missing in majority of lung cancer samples, indicating its protective role. This breakthrough could lead to early screening techniques and treatments for lung cancer.
Researchers found that combining PI3K and MEK inhibitors led to significant tumor shrinkage in mice with lung cancer driven by K-Ras mutations. The combination treatment eradicated the tumors with minimal toxicity, providing a strong rationale for testing this therapy in human trials.
According to a recent report, cancer incidence and mortality have declined in the US for the first time among both men and women. The decline is attributed to decreases in the most common cancers, including prostate, lung, and colorectal cancer.
The report found declines in both cancer incidence and death rates, as well as wide variations in lung cancer trends from state to state. Tobacco control measures are key to reducing the risk of lung cancer.
The report reveals declines in cancer incidence and death rates across the US, with some states experiencing significant variations in lung cancer trends. These findings underscore the need to strengthen tobacco control programs and accelerate efforts to prevent or reduce the occurrence of kidney and liver cancers.
A team of researchers found that a tiny protein called alpha-catenin is essential for forming strong bonds between cells. Cancer cells with dysfunctional alpha-catenin can break free and spread the disease, but scientists may be able to develop therapies to repair or replace this protein and prevent cancer's progression.
The INTEREST study found oral gefitinib comparable to injected docetaxel in non-small cell lung cancer patients, with better quality of life. Common side effects included rash and diarrhoea with gefitinib, while neutropenia and asthenic disorders were more common with docetaxel.
A study published by the American Association for Cancer Research found that cruciferous vegetables like broccoli may lower lung cancer risk in smokers. The study showed a significant protective effect, with risks ranging from 20% to 55% depending on the type and duration of smoking.
Researchers studied DNA methylation in former smokers and found differences between those with lung cancer and disease-free individuals. Altered methylation levels may explain why some former smokers develop lung cancer despite quitting smoking.
A study found that African-American patients with non-small cell lung cancer have a higher copy number of the epidermal growth factor receptor (EGFR) gene, predicting better long-term outcomes when taking erlotinib and gefitinib. Few EGFR mutations were observed, highlighting the need for more research in this patient population.
A recent study published by the American Society for Radiation Oncology found that males diagnosed with non-small cell lung cancer have a higher mortality rate than females. The research also revealed that gender is a significant prognostic factor in lung cancer patients' overall survival rates.
A phase III clinical trial found that adding bevacizumab to erlotinib therapy improves progression-free survival in advanced non-small cell lung cancer patients, but not overall survival. The combination also shows a response rate and tumor shrinkage.
A multi-center phase II clinical trial found improved survival in patients with advanced non-small cell lung cancer treated with chemotherapy and targeted therapies bevacizumab and cetuximab. The combination showed no safety concerns, indicating a potential future treatment option for lung cancer.
Researchers found that proton therapy with concurrent chemotherapy significantly reduced bone marrow toxicity in patients with locally advanced non-small cell lung cancer, improving treatment efficacy and patient outcomes. The study suggests proton therapy as a safer option for vulnerable patients, including children and the elderly.
A study led by The University of Texas M. D. Anderson Cancer Center has found a four-drug regimen of carboplatin, paclitaxel, bevacizumab, and cetuximab to be safe for patients with advanced lung cancer. The regimen showed modest improvement in survival rate, with 53% of patients experiencing tumor shrinkage.
A new Cornell study found a strong relationship between allergies and cancer in tissues exposed to environmental factors, such as eczema, hives, and hay fever. Allergies linked to these conditions were most strongly associated with lower rates of cancers in exposed tissues.
Researchers found that allergy symptoms may protect against cancer by removing foreign particles and substances from organs that come into contact with them. However, the relationship between asthma and lung cancer is a special case where asthma actually increases lung cancer rates.
Researchers found that video-assisted thoracic surgery (VATS) for stage I non-small cell lung cancer results in shorter post-operative hospital stays and faster removal of chest tubes compared to traditional open surgery. The study also showed comparable outcomes in terms of surgical success and complication rates.